Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Managing Specialty Drug Costs as Top Employer Concern

Posted by Matt Breese on Apr 12, 2018

As costs for specialty drugs continue to rise, managing those costs remains employers’ top concern, according to a recent Pharmacy Benefit Management Institute (PBMI) study.
 
Since 2011, medical benefit spending has risen 55%, and “double-digit average specialty trend under the pharmacy benefit has been the norm since 2007,” notes PBMI’s 2018 Trends in Specialty Drug Benefits
 
Read More

Topics: Industry Trends, Data & Analytics, Payer

Trends That Matter for Drug Expenditures

Posted by Matt Breese on Mar 15, 2018

Prime Therapeutics reported overall drug expenditures decrease across all three of its business lines in 2017. 

Specifically, the PBM said it lowered drug trend to -0.2% for commercial, -0.8% for Medicare Part D and -5.4% for Medicaid in 2017. The drug trend in 2016 was 2.5% for commercial, -0.7% for Medicare and 6.9% for Medicaid.

Read More

Topics: Industry Trends, Data & Analytics

Perspectives on Analytics Revolution in the Life Sciences Industry

Posted by Matt Breese on Mar 6, 2018

Looking ahead, life sciences companies should focus on making full use of analytics to translate insights to action, given that the industry is undergoing a transformative shift. 

Over the past few years, life sciences companies have been able to make more sophisticated and precise advances. Yet instead of changing decisions, their insights remain diagnostic. In 2018, leading brands should keep investing in infrastructure and rapid experimentation to generate prescriptive analytics. 

Read More

Topics: Industry Trends, Data & Analytics, Branding & Marketing

Perspectives on Triggered Messages

Posted by Matt Breese on Feb 6, 2018

Data is nothing new to pharmaceutical marketers, who have become accustomed to using data to generate triggered messages, a near-real-time reaction to certain events or decisions, to their providers.
 
The next step is to go beyond simple messaging and personally tailor the message across varied platforms by using analytics and predictive tools, says Jose Ferreira, vice president of customer experience and data management at CMI/Compas. 
 
Read More

Topics: Data & Analytics, Branding & Marketing

Trends That Matter for HGH Treatments

Posted by Matt Breese on Jan 11, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is human growth hormone (HGH) treatments. 

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Read More

Topics: Market Access, Data & Analytics

MMIT Reality Check on Growth Hormones (Jan 2018)

Posted by Matt Breese on Jan 8, 2018

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Data & Analytics, Branding & Marketing

Perspectives on Wearable Device Data

Posted by Matt Breese on Dec 27, 2017

In 2018, we will see a rising amount of health-related data generated from personal devices such as smartphones and wearables. One potential application for these tools is to monitor patients in clinical trials remotely.
 
Historically, some concerns with wearable device-derived data have been the lack of regulatory guidance and the difficulty of ensuring data quality.
 
Read More

Topics: Data & Analytics

Perspectives on Real-World Data

Posted by Matt Breese on Nov 7, 2017

The pharmaceutical industry has seen an explosion in the availability of real-world data in recent years. In the past, pharma companies mainly relied on data from clinical trials. Today, real-world data provides new insights and opportunities to assess a broader population.

This information is increasingly influencing healthcare decision-makers. However, data scientists must have the skills to sort through unstructured health data, analyze it, understand the big picture, and portray the data visually. 

Read More

Topics: Industry Trends, Data & Analytics

Perspectives on Translating Data into Powerful Stories

Posted by Matt Breese on Aug 1, 2017

Mark Twain popularized the saying, “There are three kinds of lies: lies, damned lies and statistics.” We often think that including numbers in a presentation will engage our audience – isn’t the data evidence enough to make our audience take note and pay attention?

No. Most sales and marketing teams armed with a wealth of data struggle to deliver meaning in a context that’s relevant.

Read More

Topics: Market Access, Data & Analytics

MMIT Reality Check on Growth Hormones (Jul 2017)

Posted by Matt Breese on Jul 18, 2017

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Data & Analytics, Branding & Marketing